FDA approves Freenome SimpleScreen CRC blood test as Abbott prepares US launch
FDA approves Freenome’s SimpleScreen CRC blood test as Abbott plans a fall launch. See its benefits, limits and colonoscopy requirement.
FDA approves Freenome’s SimpleScreen CRC blood test as Abbott plans a fall launch. See its benefits, limits and colonoscopy requirement.
Find out how Dexcom G7 data could reshape CGM adoption for type 2 diabetes patients not using insulin.
Abbott has PFA momentum, but rhythm care is becoming a platform battle. Can clinical data turn into durable adoption?